Prospective evaluation of retinal toxicity of platinum-based chemotherapy in patients with testicular cancer (RETOX-study)

Prospective evaluation of retinal toxicity of platinum-based chemotherapy in patients with testicular cancer (RETOX-study) - RETOX-Study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00016166

Enrollment

Registered

2018-12-27

Start date

2019-05-20

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C62 S04.0

Interventions

Group 1: Ophthalmological examination before initiation, as well as 1, 6, and 12 months upon completion of platinum-based chemotherapy in patients diagnosed with testicular cancer.

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - patients diagnosed with testicular cancer - indication for platinum-based chemotherapy according to current guidelines - legal age - written consent

Exclusion criteria

Exclusion criteria: - any kind of eye-disease - minority (nonage) - ongoing legal care - prior chemotherapy

Design outcomes

Primary

Measure	Time frame
Retinal alterations one months upon completion of platinum-based chemotherapy, defined as alterations of the retinal nerve fiber thickness in µm	—

Countries

Germany

Contacts

Public ContactLuis Kluth

gOA Uniklinik Frankfurt

luis.kluth@kgu.de069630180069

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026